

REMARKS


The Applicants hereby elect to prosecute the claims of Group II, claims 8-10, with traverse. Claim 15 has been rewritten to depend from Claim 9, in that the same method step utilizing selection of cells from a leukemia sample not only provides for a cellular composition, but also provides information about the nature of cells present in the sample. Applicants submit that the essential features of both Groups II and III relate to the selection of cells from a hematologic sample using markers such as Thy-1, IL-7R α (CD127), and a lineage panel, which can distinguish hematopoietic stem and progenitor subsets. Rejoinder is requested.

The Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number STAN-340.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 3, 2009

By: 
Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231